238 related articles for article (PubMed ID: 36084923)
1. Mitochondria-targeting folic acid-modified nanoplatform based on mesoporous carbon and a bioactive peptide for improved colorectal cancer treatment.
Wang J; Zhang L; Xin H; Guo Y; Zhu B; Su L; Wang S; Zeng J; Chen Q; Deng R; Wang Z; Wang J; Jin X; Gui S; Xu Y; Lu X
Acta Biomater; 2022 Oct; 152():453-472. PubMed ID: 36084923
[TBL] [Abstract][Full Text] [Related]
2. Colon tissue-accumulating mesoporous carbon nanoparticles loaded with
Zhang L; Gui S; Xu Y; Zeng J; Wang J; Chen Q; Su L; Wang Z; Deng R; Chu F; Liu W; Jin X; Lu X
Theranostics; 2021; 11(7):3417-3438. PubMed ID: 33537095
[TBL] [Abstract][Full Text] [Related]
3. Folic acid-decorated alginate nanoparticles loaded hydrogel for the oral delivery of diferourylmethane in colorectal cancer.
Abbasi M; Sohail M; Minhas MU; Mahmood A; Shah SA; Munir A; Kashif MU
Int J Biol Macromol; 2023 Apr; 233():123585. PubMed ID: 36758757
[TBL] [Abstract][Full Text] [Related]
4. A smart pH-responsive nano-carrier as a drug delivery system for the targeted delivery of ursolic acid: suppresses cancer growth and metastasis by modulating P53/MMP-9/PTEN/CD44 mediated multiple signaling pathways.
Jiang K; Chi T; Li T; Zheng G; Fan L; Liu Y; Chen X; Chen S; Jia L; Shao J
Nanoscale; 2017 Jul; 9(27):9428-9439. PubMed ID: 28660943
[TBL] [Abstract][Full Text] [Related]
5. Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC).
Song Y; Zhou B; Du X; Wang Y; Zhang J; Ai Y; Xia Z; Zhao G
Biomed Pharmacother; 2020 May; 125():109561. PubMed ID: 32106385
[TBL] [Abstract][Full Text] [Related]
6. Trimethyl chitosan based conjugates for oral and intravenous delivery of paclitaxel.
He R; Yin C
Acta Biomater; 2017 Apr; 53():355-366. PubMed ID: 28189812
[TBL] [Abstract][Full Text] [Related]
7. Dual-Targeting Multifuntional Mesoporous Silica Nanocarrier for Codelivery of siRNA and Ursolic Acid to Folate Receptor Overexpressing Cancer Cells.
Zheng G; Shen Y; Zhao R; Chen F; Zhang Y; Xu A; Shao J
J Agric Food Chem; 2017 Aug; 65(32):6904-6911. PubMed ID: 28771340
[TBL] [Abstract][Full Text] [Related]
8. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
9. Unraveling the Effect of Breast Cancer Patients' Plasma on the Targeting Ability of Folic Acid-Modified Chitosan Nanoparticles.
Nemati M; Bani F; Sepasi T; Zamiri RE; Rasmi Y; Kahroba H; Rahbarghazi R; Sadeghi MR; Wang Y; Zarebkohan A; Gao H
Mol Pharm; 2021 Dec; 18(12):4341-4353. PubMed ID: 34779630
[TBL] [Abstract][Full Text] [Related]
10. Hydroxylated Mesoporous Nanosilica Coated by Polyethylenimine Coupled with Gadolinium and Folic Acid: A Tumor-Targeted T(1) Magnetic Resonance Contrast Agent and Drug Delivery System.
Zhang G; Gao J; Qian J; Zhang L; Zheng K; Zhong K; Cai D; Zhang X; Wu Z
ACS Appl Mater Interfaces; 2015 Jul; 7(26):14192-200. PubMed ID: 26084052
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of adenosine 5'-triphosphate using chitosan-coated mesoporous hydroxyapatite: A theranostic pH-sensitive nanoplatform with enhanced anti-cancer effect.
Feiz MS; Meshkini A
Int J Biol Macromol; 2019 May; 129():1090-1102. PubMed ID: 30170062
[TBL] [Abstract][Full Text] [Related]
12. A two-step precise targeting nanoplatform for tumor therapy via the alkyl radicals activated by the microenvironment of organelles.
Wang L; Niu X; Song Q; Jia J; Hao Y; Zheng C; Ding K; Xiao H; Liu X; Zhang Z; Zhang Y
J Control Release; 2020 Feb; 318():197-209. PubMed ID: 31672622
[TBL] [Abstract][Full Text] [Related]
13. Nanoplatform based on GSH-responsive mesoporous silica nanoparticles for cancer therapy and mitochondrial targeted imaging.
He H; Meng S; Li H; Yang Q; Xu Z; Chen X; Sun Z; Jiang B; Li C
Mikrochim Acta; 2021 Apr; 188(5):154. PubMed ID: 33821295
[TBL] [Abstract][Full Text] [Related]
14. Theranostic pH-sensitive nanoparticles for highly efficient targeted delivery of doxorubicin for breast tumor treatment.
Pan C; Liu Y; Zhou M; Wang W; Shi M; Xing M; Liao W
Int J Nanomedicine; 2018; 13():1119-1137. PubMed ID: 29520140
[TBL] [Abstract][Full Text] [Related]
15. Oral delivery of pH-responsive alginate microbeads incorporating folic acid-grafted solid lipid nanoparticles exhibits enhanced targeting effect against colorectal cancer: A dual-targeted approach.
Rajpoot K; Jain SK
Int J Biol Macromol; 2020 May; 151():830-844. PubMed ID: 32061847
[TBL] [Abstract][Full Text] [Related]
16. Cytocompatible chitosan-graft-mPEG-based 5-fluorouracil-loaded polymeric nanoparticles for tumor-targeted drug delivery.
Antoniraj MG; Ayyavu M; Henry LJK; Nageshwar Rao G; Natesan S; Sundar DS; Kandasamy R
Drug Dev Ind Pharm; 2018 Mar; 44(3):365-376. PubMed ID: 28835136
[TBL] [Abstract][Full Text] [Related]
17. Folate-polyethyleneimine functionalized mesoporous carbon nanoparticles for enhancing oral bioavailability of paclitaxel.
Wan L; Wang X; Zhu W; Zhang C; Song A; Sun C; Jiang T; Wang S
Int J Pharm; 2015 Apr; 484(1-2):207-17. PubMed ID: 25724138
[TBL] [Abstract][Full Text] [Related]
18. Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading paclitaxel and tanshinone IIA for the treatment of acute promyelocytic leukemia.
Li Z; Zhang Y; Zhu C; Guo T; Xia Q; Hou X; Liu W; Feng N
Int J Pharm; 2020 Aug; 586():119576. PubMed ID: 32603839
[TBL] [Abstract][Full Text] [Related]
19. Tumor Targeted Curcumin Delivery by Folate-Modified MPEG-PCL Self-Assembly Micelles for Colorectal Cancer Therapy.
Hu Y; He Y; Ji J; Zheng S; Cheng Y
Int J Nanomedicine; 2020; 15():1239-1252. PubMed ID: 32110020
[TBL] [Abstract][Full Text] [Related]
20. Folic acid-decorated PEGylated magnetite nanoparticles as efficient drug carriers to tumor cells overexpressing folic acid receptor.
Movileanu C; Anghelache M; Turtoi M; Voicu G; Neacsu IA; Ficai D; Trusca R; Oprea O; Ficai A; Andronescu E; Calin M
Int J Pharm; 2022 Sep; 625():122064. PubMed ID: 35952802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
